Threshold Pharma (THLD) Reports Data on Evofosfamide in Relapsed/Refractory Multiple Myeloma to Be Presented at ASCO
Tweet Send to a Friend
Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that new clinical data from its ongoing Phase 2 clinical trial evaluating evofosfamide ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
